The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients.
Medical oncologist Dr. Jennifer Knox independently reviewed a U.S.-led study of the experimental drug daraxonrasib and calls the results “amazing.”
The randomized Phase 3 clinical trial of 500 pancreatic cancer patients found those who took the daily pill survived for more than a year compared to just over six months for patients who had chemotherapy alone.
Manufacturer Revolution Medicines has applied to the U.S. Food and Drug Administration to license the drug….